Legal status · Canada
Is DT2216 legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. DT2216 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
DT2216 in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Health Canada approval status | Not approved by Health Canada; investigational |
| Human studies cited | 4 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the DT2216 profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
DT2216 is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What DT2216 is
The engineered answer to the navitoclax platelet problem: a degrader that hands BCL-xL to an E3 ligase platelets barely express. In the first human trial, 20 patients with solid tumours, only one dose-limiting toxicity occurred, a grade 4 thrombocytopenia that resolved within 48 hours.
Navitoclax kills senescent cells and platelets through the same target. DT2216 was designed around that.
Mechanism: Established in human cell lines and mice, with the intended platelet sparing now supported by human phase 1 data: DT2216 binds BCL-xL and recruits the VHL E3 ubiquitin ligase, marking BCL-xL for proteasomal degradation. Because VHL is minimally expressed in platelets, the degradation is inefficient there.
Regulatory history: Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered.
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for DT2216 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
DT2216 in other countries
Frequently asked questions
Is DT2216 legal in Canada?
No. DT2216 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy DT2216 in Canada?
No approved product exists to buy. In Canada DT2216 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is DT2216 Health Canada approved?
No. In Canada DT2216 is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered.. On the evidence, 4 human studies are cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for DT2216 live on its compound profile.
DT2216 profileThis page is general information about the regulatory status of DT2216 in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.